InvestorsHub Logo
Followers 205
Posts 9785
Boards Moderated 6
Alias Born 10/02/2010

Re: namtae post# 18258

Wednesday, 08/22/2018 1:15:13 AM

Wednesday, August 22, 2018 1:15:13 AM

Post# of 21373
Well, garsh namtae. Thanks.

I think everyone understands that ONCX will need more funding.

dont forget the Notes start coming due early 2019.



Forget? I have been pointing out that the notes have been renegotiated for several weeks. I predicted it months ago.

Isnt it curious to anyone that the notes are now due in April 2019, at the same time ONCX CEO Redman has publically stated that updates will be provided before then?

All the while, not a word about the mid dose study. My guess, its been a disaster or we would've heard something by now



Really? Your guess seems to contradict the opinions and actions of note holders who will lose their own investment if their isnt a positive update in 2018.

Lets keep in mind that ONCX’s principal shareholder is Greenville Health became a non-profit 501c3 in late 2016.

It makes it easier for Greenville to solicit grants from the government and contributions from foundations and charities. All who have contributed to Prolanta research in the past.

This is worth noting because Jerry R. Youkey, MD is not only an ONCX BOD member, but also Chief Academic Officer and an Authorized Organizational Representative involved in the GHS Grant Proposal process according to the GHS website.

https://hsc.ghs.org/research/grants/grant-proposal-information/

Also remember that the recent ONCX BOD appointment of Sherry Grisewood in June 2018, came from a company that secured almost $20,000,000 in grants for FDA trials, just a few weeks ago.

ONCX is looking pretty solid based on currently available information.

GLTA, IMO and FWIW.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.